強気
$444.76
シナリオ価格
$470.440
+9.879 (+2.10%)終値時点
HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom.
HCA Healthcare Inc is a good buy right now due to its current price of $451.09 being below the analyst price target of $495, indicating a potential upside of about 9.7%. Additionally, the stock has a strong forward P/E ratio of 13.85, suggesting it is undervalued compared to its growth potential. The recent positive momentum, with a 5-day change of +5.72% and an RSI of 76.97, indicates strong buying interest, although it is approaching overbought territory. The main risk is the insider selling, which has increased by 1487.91% over the last month, indicating potential concerns about future performance.
TD Cowen
$460
2026-10-12
TD Cowen
2026-10-12
目標株価
$460
RBC Capital
$496
2026-10-07
RBC Capital
2026-10-07
目標株価
$496
BMO Capital
$495
2026-09-22
BMO Capital
2026-09-22
目標株価
$495
JPMorgan
$425
2026-08-20
JPMorgan
2026-08-20
目標株価
$425
BofA
$425
2026-08-10
BofA
2026-08-10
目標株価
$425
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

HCA Healthcare Announces Q3 2026 Earnings Call Details

HCA Healthcare Presents Annual Awards of Distinction

BMO Capital Initiates Coverage of HCA Healthcare with Outperform Rating

Latest Wall Street Ratings Overview

Technical Analysis of HCA Stock Patterns
HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).
HCA Healthcare Inc is a good buy right now due to its current price of $451.09 being below the analyst price target of $495, indicating a potential upside of about 9.7%. Additionally, the stock has a strong forward P/E ratio of 13.85, suggesting it is undervalued compared to its growth potential. The recent positive momentum, with a 5-day change of +5.72% and an RSI of 76.97, indicates strong buying interest, although it is approaching overbought territory. The main risk is the insider selling, which has increased by 1487.91% over the last month, indicating potential concerns about future performance.
22 analysts cover HCA: 16 rate it Buy, 6 Hold and 0 Sell. The average price target is 491.89.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。